Jpmorgan Chase & CO Revance Therapeutics, Inc. Transaction History

Jpmorgan Chase & CO

$1.22 Trillion
Q3 2024

A detailed history of Jpmorgan Chase & CO transactions in Revance Therapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 134,181 shares of RVNC stock, worth $344,845. This represents 0.0% of its overall portfolio holdings.

Number of Shares

134,181

Previous 2,944,861 95.44%

Holding current value

$344,845

Previous $7.57 Million 95.45%

% of portfolio

0.0%

Previous 0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 08, 2024	SELL	$2.57 - $2.57 $7.22 Million - $7.22 Million	-2,810,680 Reduced 95.44%	134,181 $344,000
Q2 2024 Aug 12, 2024	SELL	$2.34 - $4.73 $487,333 - $985,079	-208,262 Reduced 6.6%	2,944,861 $7.57 Million
Q1 2024 May 10, 2024	SELL	$4.65 - $9.31 $6.93 Million - $13.9 Million	-1,490,296 Reduced 32.09%	3,153,123 $15.5 Million
Q4 2023 Feb 12, 2024	BUY	$5.81 - $11.2 $76,819 - $148,086	13,222 Added 0.29%	4,643,419 $40.8 Million
Q3 2023 Nov 14, 2023	SELL	$11.47 - $25.07 $730,535 - $1.6 Million	-63,691 Reduced 1.36%	4,630,197 $53.1 Million
Q2 2023 Aug 11, 2023	SELL	$24.7 - $37.61 $11.6 Million - $17.7 Million	-470,269 Reduced 9.11%	4,693,888 $119 Million
Q1 2023 May 18, 2023	BUY	$18.36 - $35.27 $1.88 Million - $3.6 Million	102,144 Added 2.02%	5,164,157 $166 Million
Q1 2023 May 11, 2023	BUY	$18.36 - $35.27 $873,770 - $1.68 Million	47,591 Added 0.95%	5,062,013 $163 Million
Q4 2022 Feb 13, 2023	SELL	$18.32 - $30.66 $7.99 Million - $13.4 Million	-436,076 Reduced 8.0%	5,014,422 $92.6 Million
Q3 2022 Nov 14, 2022	SELL	$14.33 - $28.47 $17.7 Million - $35.2 Million	-1,237,427 Reduced 18.5%	5,450,498 $147 Million
Q2 2022 Aug 11, 2022	SELL	$11.52 - $20.4 $1.49 Million - $2.64 Million	-129,280 Reduced 1.9%	6,687,925 $92.4 Million
Q1 2022 May 11, 2022	SELL	$12.36 - $20.31 $1.35 Million - $2.22 Million	-109,201 Reduced 1.58%	6,817,205 $133 Million
Q4 2021 Feb 10, 2022	BUY	$12.46 - $27.87 $23 Million - $51.4 Million	1,844,101 Added 36.28%	6,926,406 $113 Million
Q3 2021 Nov 12, 2021	BUY	$25.78 - $33.21 $131 Million - $169 Million	5,082,305 New	5,082,305 $142 Million

Others Institutions Holding RVNC

# of Institutions

234

Shares Held

82.8M

Call Options Held

680K

Put Options Held

896K

View Full List

About Revance Therapeutics, Inc.

Ticker RVNC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,305,696
Market Cap $212M
Description
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...

More about RVNC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Revance Therapeutics, Inc. Transaction History